MedPath

IX BIOPHARMA PTY LTD

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:4

Trial Phases

2 Phases

Phase 1:3
Phase 2:1

Drug Approvals

41

TGA:41

Drug Approvals

NAD+ 100mg (480825)

Product Name
NAD+ 100mg
Approval Date
Feb 26, 2025
TGA

SL-NAD+ 100mg (469505)

Product Name
SL-NAD+ 100mg
Approval Date
Nov 20, 2024
TGA

Entity RadianiX (467407)

Product Name
Entity RadianiX
Approval Date
Nov 6, 2024
TGA

Entity SL-NAD+ 100mg (459386)

Product Name
Entity SL-NAD+ 100mg
Approval Date
Aug 13, 2024
TGA

SL NAD+ (451685)

Product Name
SL NAD+
Approval Date
Jun 11, 2024
TGA

Xativa Sleep 20mg/5mg (430030)

Product Name
Xativa Sleep 20mg/5mg
Approval Date
Dec 6, 2023
TGA

MELTMED Regenerate (413150)

Product Name
MELTMED Regenerate
Approval Date
Jul 10, 2023
TGA

Xativa 50mg (407354)

Product Name
Xativa 50mg
Approval Date
Apr 5, 2023
TGA

Entity RadianiX (379157)

Product Name
Entity RadianiX
Approval Date
Nov 26, 2021
TGA

Brillar (378410)

Product Name
Brillar
Approval Date
Nov 22, 2021
TGA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (75.0%)
Phase 2
1 (25.0%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.